查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1424453

鲍氏不动桿菌肺炎药物的全球市场：按药物类别、给药途径和地区划分

Global Acinetobacter Pneumonia Therapeutics Market, By Drug Class, By Route of Administration, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 132 Pages | 商品交期: 2-3个工作天内

价格
简介目录

全球鲍氏不动桿菌肺炎治疗市场规模预计将从 2023 年的 6.146 亿美元增加到 2030 年的 8.991 亿美元，预测期内复合年增长率为 5.6%。

报告范围 报告详情
基准年 2022年 2023/2024年市场规模 6.146 亿美元
实际资料 2018-2021 预测期 2023-2030
预测期间 2023/2024 至 2030/2031 年复合年增长率： 5.60% 2030/2031价值预测 8.991 亿美元
图 1. 2023 年鲍氏不动桿菌肺炎治疗药物的全球市场占有率（按地区划分）
全球不动桿菌肺炎治疗市场-IMG1

鲍氏不动桿菌肺炎是一种由鲍氏不动桿菌属细菌引起的一种严重肺炎。这些细菌常见于土壤和水中。近年来，多重抗药性鲍氏不动桿菌桿菌引起的院内肺炎病例迅速增加。它通常影响免疫力缺乏的患者和在加护病房接受机械通气的患者。抗生素抗药性是鲍氏不动桿菌肺炎治疗的一个主要问题。目前需要针对这种病原体的新治疗方法。

市场动态：

全球鲍氏不动桿菌肺炎治疗市场是由抗药性菌株的流行和院内或人工呼吸器相关肺炎发病率的增加所推动的。根据美国疾病管制与预防美国，每年美国院内肺炎病例中，鲍氏不动桿菌感染疾病占 8% 至 10%。此外，有限的抗生素管道和缺乏专门针对鲍氏不动桿菌肺炎的核准治疗方法为该市场带来了机会。然而，高昂的开发成本和与新药认证相关的监管障碍正在阻碍市场开拓。该市场受到多重抗药性菌株发病率增加、诊断技术进步以及对有效治疗方案的需求等因素的影响。製药公司、研究机构和医疗保健提供者之间的合作在推动治疗解决方案方面发挥关键作用。不断变化的感染疾病情势和 COVID-19 大流行的影响凸显了透过创新治疗性介入和公共卫生措施持续努力应对鲍氏不动桿菌肺炎的重要性。

本研究的主要特点

该报告对全球鲍氏不动桿菌肺炎治疗市场进行了详细分析，并提供了以2022年为基准年的预测期（2023-2030）的市场规模和年复合成长率（CAGR%）。

它揭示了各个细分市场的潜在收益成长机会，并为该市场说明了一系列有吸引力的投资提案。

它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的主要考察。

根据公司亮点、产品系列、主要亮点、绩效和策略等参数对全球鲍氏不动桿菌肺炎治疗药物市场的主要企业进行了分析。

该报告的见解将使行销人员和公司负责人能够就未来的产品发布、升级、市场扩张和行销策略做出明智的决策。

全球鲍氏不动桿菌肺炎治疗药物市场报告针对该行业的各个相关人员，如投资者、供应商、产品製造商、分销商、新进业者和财务分析师。

透过用于分析全球鲍氏不动桿菌肺炎治疗药物市场的各种策略矩阵，将促进相关人员的决策。

目录

第一章 研究目的与前提

  • 研究目标
  • 先决条件
  • 简称

第二章 市场展望

  • 报告说明
    • 市场定义和范围
  • 执行摘要
  • Coherent Opportunity Map（COM）

第三章市场动态、法规及趋势分析

  • 市场动态
  • 影响分析
  • 主要亮点
  • 监管场景
  • 服务交付组合
  • PEST分析
  • 波特的分析
  • 併购场景
  • 管道分析

第四章全球鲍氏不动桿菌肺炎治疗药物市场 - 冠状病毒（COVID-19）大流行的影响

  • 新型冠状病毒感染疾病（COVID-19）的流行病学
  • 供需面分析
  • 经济影响

第五章2018-2030年全球鲍氏不动桿菌肺炎治疗药物市场（依药物类别）

  • 头孢菌素
  • 碳青霉烯类
  • Aminoglycosides
  • 多粘菌素

第六章全球鲍氏不动桿菌肺炎治疗药物市场，依给药途径，2018-2030

  • 口服
  • 静脉
  • 其他的

第七章2018-2030年全球鲍氏不动桿菌肺炎治疗药物市场（按地区）

  • 北美洲
  • 美国
  • 加拿大
  • 欧洲
  • 德国
  • 英国
  • 西班牙
  • 法国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • ASEAN
  • 其他亚太地区
  • 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 海湾合作委员会国家
  • 以色列
  • 其他中东地区
  • 非洲
  • 北非
  • 中部非洲
  • 南非

第八章 竞争形势

  • Pfizer Inc.
    • Drug Class Portfolio
  • Merck & Co., Inc.
  • GlaxoSmithKline plc（GSK）
  • AstraZeneca plc
  • Novartis AG
  • Johnson & Johnson
  • Sanofi SA
  • Bayer AG
  • Basilea Pharmaceutica

第9章 章节

  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI6566

The global acinetobacter pneumonia therapeutics market size is expected to reach US$ 899.1 Mn by 2030, from US$ 614.6 Mn in 2023, exhibiting a CAGR of 5.6% during the forecast period.

Report Coverage Report Details
Base Year: 2022 Market Size in 2023/2024: US$ 614.6 Mn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023/2024 to 2030/2031 CAGR: 5.60% 2030/2031 Value Projection: US$ 899.1 Mn
Figure 1. Global Acinetobacter Pneumonia Therapeutics Market Share (%), By Region, 2023
Global Acinetobacter Pneumonia Therapeutics Market - IMG1

Acinetobacter pneumonia is a severe type of pneumonia caused by the Acinetobacter species of bacteria. These bacteria are commonly found in soil and water. In recent times, there has been a steep rise in the number of cases of hospital-acquired pneumonia caused by multidrug-resistant Acinetobacter strains. Typically, it affects immunocompromised patients or those on mechanical ventilation in intensive care units. Antibiotic resistance has emerged as a major challenge in treating Acinetobacter pneumonia. Novel therapeutic approaches targeting this pathogen are the need of the hour.

Market Dynamics:

The global Acinetobacter pneumonia therapeutics market is driven by the growing prevalence of drug-resistant strains and increasing incidence of hospital-acquired or ventilator-associated pneumonia. According to the Centers for Disease Control and Prevention, Acinetobacter infections account for 8-10% of all hospital-acquired pneumonia cases in the U.S. every year. Moreover, the restricted antibacterial pipeline and lack of approved therapies specific to Acinetobacter pneumonia act as opportunities in the market. However, high development costs and regulatory hurdles associated with new drug approvals hamper the market growth. The market is influenced by factors such as increasing incidence of multidrug-resistant strains, advancements in diagnostic technologies, and the need for effective treatment options. Collaborations between pharmaceutical companies, research institutions, and healthcare providers play a crucial role in advancing therapeutic solutions. The evolving landscape of infectious diseases and the impact of the COVID-19 pandemic underscore the importance of sustained efforts to address Acinetobacter pneumonia through innovative therapeutic interventions and public health measures.

Key Features of the Study:

This report provides an in-depth analysis of the global acinetobacter pneumonia therapeutics market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year

It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global acinetobacter pneumonia therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc (GSK), AstraZeneca plc, Novartis AG, Johnson & Johnson, Sanofi S.A., Bayer AG, and Basilea Pharmaceutica

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global acinetobacter pneumonia therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acinetobacter pneumonia therapeutics market.

Detailed Segmentation:

  • Global Acinetobacter Pneumonia Therapeutics Market, By Drug Class
    • Cephalosporins
    • Carbapenems
    • Aminoglycosides
    • Polymyxins
  • Global Acinetobacter Pneumonia Therapeutics Market, By Route of Administration
    • Oral
    • Intravenous
    • Others
  • Global Acinetobacter Pneumonia Therapeutics Market, By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Global Acinetobacter Pneumonia Therapeutics Market, Key Players
    • Pfizer Inc.
    • Merck & Co., Inc.
    • GlaxoSmithKline plc (GSK)
    • AstraZeneca plc
    • Novartis AG
    • Johnson & Johnson
    • Sanofi S.A.
    • Bayer AG
    • Basilea Pharmaceutica

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Acinetobacter Pneumonia Therapeutics Market, By Drug Class
    • Global Acinetobacter Pneumonia Therapeutics Market, By Route of Administration
    • Global Acinetobacter Pneumonia Therapeutics Market, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Rising prevalence of Acinetobacter pneumonia infections
    • Increasing research & development activities
    • Growing healthcare expenditure
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Service offering Portfolio
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario
  • Pipeline Analysis

4. Global Acinetobacter Pneumonia Therapeutics Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Acinetobacter Pneumonia Therapeutics Market, By Drug Class, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Cephalosporins
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Carbapenems
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Aminoglycosides
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Polymyxins
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)

6. Global Acinetobacter Pneumonia Therapeutics Market, By Route of Administration, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Intravenous
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)

7. Global Acinetobacter Pneumonia Therapeutics Market, By Region, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Region, 2019 - 2030
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2018-2030,(US$ Mn)
  • North Africa
  • Central Africa
  • South Africa

8. Competitive Landscape

  • Pfizer Inc.
    • Company Highlights
    • Drug Class Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Merck & Co., Inc.
  • GlaxoSmithKline plc (GSK)
  • AstraZeneca plc
  • Novartis AG
  • Johnson & Johnson
  • Sanofi S.A.
  • Bayer AG
  • Basilea Pharmaceutica
  • Analyst Views

9. Section

  • Research Methodology
  • About us